Aeglea Bio Therapeutics IncNASDAQ:AGLENASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5040
- TODAY'S CHANGE (%)0.0140 (2.8571%)
- Bid / Lots0.4819/ 14
- Ask / Lots0.5050/ 14
- Open / Previous Close0.5010 / 0.4900
- Day Range
- 52 Week Range
- Volume232,347
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGLE |
|---|---|---|
| 09:32 ET | 948 | 0.52 |
| 09:44 ET | 4816 | 0.516739 |
| 09:46 ET | 4283 | 0.52 |
| 09:51 ET | 4200 | 0.52 |
| 09:55 ET | 100 | 0.5149 |
| 09:57 ET | 2420 | 0.4901 |
| 10:02 ET | 40200 | 0.51 |
| 10:06 ET | 200 | 0.51 |
| 10:09 ET | 500 | 0.509899 |
| 10:11 ET | 200 | 0.51 |
| 10:18 ET | 200 | 0.4902 |
| 10:22 ET | 200 | 0.5 |
| 10:26 ET | 175 | 0.505 |
| 10:36 ET | 300 | 0.505 |
| 10:49 ET | 3900 | 0.505 |
| 10:56 ET | 100 | 0.505 |
| 10:58 ET | 2300 | 0.5002 |
| 11:00 ET | 951 | 0.5013 |
| 11:05 ET | 250 | 0.5002 |
| 11:07 ET | 600 | 0.5025 |
| 11:14 ET | 1000 | 0.5023 |
| 11:21 ET | 100 | 0.505 |
| 11:25 ET | 100 | 0.505 |
| 11:45 ET | 19901 | 0.5003 |
| 11:48 ET | 300 | 0.505 |
| 11:50 ET | 2000 | 0.5002 |
| 11:52 ET | 701 | 0.5003 |
| 11:57 ET | 100 | 0.505 |
| 12:03 ET | 4100 | 0.505 |
| 12:10 ET | 100 | 0.505 |
| 12:12 ET | 188 | 0.504208 |
| 12:15 ET | 11400 | 0.5005 |
| 12:21 ET | 200 | 0.5004 |
| 12:24 ET | 600 | 0.503 |
| 12:28 ET | 1200 | 0.505 |
| 12:32 ET | 100 | 0.50305 |
| 12:35 ET | 1100 | 0.50305 |
| 12:37 ET | 1700 | 0.505 |
| 12:39 ET | 397 | 0.5049 |
| 12:44 ET | 474 | 0.50305 |
| 12:48 ET | 990 | 0.505 |
| 12:51 ET | 100 | 0.50305 |
| 12:55 ET | 50365 | 0.49 |
| 12:57 ET | 100 | 0.4955 |
| 01:06 ET | 100 | 0.4954 |
| 01:08 ET | 110 | 0.4953 |
| 01:11 ET | 100 | 0.4954 |
| 01:13 ET | 500 | 0.4954 |
| 01:20 ET | 100 | 0.4954 |
| 01:29 ET | 1000 | 0.5 |
| 01:33 ET | 400 | 0.4999 |
| 01:38 ET | 900 | 0.4998 |
| 01:40 ET | 200 | 0.4977 |
| 01:45 ET | 123 | 0.499078 |
| 01:47 ET | 100 | 0.4997 |
| 01:49 ET | 800 | 0.481 |
| 01:51 ET | 1500 | 0.5 |
| 01:58 ET | 300 | 0.5 |
| 02:25 ET | 1000 | 0.4949 |
| 02:32 ET | 112 | 0.498942 |
| 02:38 ET | 100 | 0.4999 |
| 02:54 ET | 300 | 0.49 |
| 02:56 ET | 100 | 0.4998 |
| 03:08 ET | 500 | 0.4998 |
| 03:14 ET | 28518 | 0.5 |
| 03:19 ET | 200 | 0.5025 |
| 03:21 ET | 100 | 0.5006 |
| 03:35 ET | 2671 | 0.5099 |
| 03:37 ET | 818 | 0.504 |
| 03:42 ET | 3641 | 0.507 |
| 03:44 ET | 2463 | 0.505 |
| 03:46 ET | 708 | 0.505 |
| 03:48 ET | 202 | 0.505 |
| 03:51 ET | 200 | 0.5049 |
| 03:53 ET | 1100 | 0.5046 |
| 03:55 ET | 2000 | 0.5046 |
| 03:57 ET | 1100 | 0.5055 |
| 04:00 ET | 5825 | 0.504 |
Jan 6, 2023
Aeglea BioTherapeutics Cuts 15% of Workforce, Halts Development Programs; COO to Leave; Shares Fall, from 11:38AM ET on Friday Jan 06, 2023 by MT Newswires
11:38AM ET on Friday Jan 06, 2023 by MT NewswiresBRIEF-Aeglea Biotherapeutics Announces Update To Corporate Structure, from 7:11AM ET on Friday Jan 06, 2023 by Thomson Reuters
7:11AM ET on Friday Jan 06, 2023 by Thomson ReutersAeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency, from 7:01AM ET on Friday Jan 06, 2023 by PR Newswire
7:01AM ET on Friday Jan 06, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aeglea Bio Therapeutics Inc | 31.0M | -0.4x | --- |
Finch Therapeutics Group Inc | 24.7M | -0.2x | --- |
Obseva SA | 22.1M | -0.2x | --- |
Landos Biopharma Inc | 16.5M | -0.3x | --- |
Codiak BioSciences, Inc. | 29.7M | -1.2x | --- |
Emmaus Life Sciences Inc | 18.8M | -1.1x | --- |
Company Information
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.
Contact Information
- Headquarters
- 805 Las Cimas Parkway, Suite 100AUSTIN, TX, United States 78746
- Phone
- 512-942-2935
- Fax
- 512-872-5121
Executives
- Independent Chairman of the board
- Russell Cox
- President, Chief Executive Officer, Director
- Jeffrey Goldberg
- Chief Financial Officer
- Jonathan Alspaugh
- General Counsel, Company Secretary
- Jim Kastenmayer
- Chief Commercial Officer, Chief Business Officer
- Michael Hanley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.0M |
|---|---|
Revenue (TTM) | $5.8M |
Shares Outstanding | 61.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.69 |
EPS | $-1.15 |
Book Value | $1.70 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 5.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,482.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
